- Allena Pharmaceuticals (NASDAQ:ALNA -0.6%) has completed an animal proof-of-concept study supporting the rationale for ALLN-346 for the treatment of hyperuricemia (excess uric acid in the blood) in gout patients with associated chronic kidney disease (CKD).
- The preclinical results will be submitted for presentation at a scientific conference in H2. A U.S. IND, allowing the company to initiate early-stage studies if approved, is on tap for H1 2019.
- ALLN-346 is an orally available non-absorbed urate-degrading enzyme designed to reduce the urate (ester of uric acid) burden on the kidney by degrading urate in the GI tract.
- Gout-related tickers: (SELB -0.5%)(IRWD -1.3%)(CBAY -1.1%)(AZN -1.1%)
Allena Pharma to file IND for ALLN-346 in H1 2019
Recommended For You
About ALNAQ Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
ALNAQ | - | - |
Allena Pharmaceuticals, Inc. |